IM was FDA-approved in 2002 (Imatinib FDA Package Insert, n.d.) and is currently used as the first line of therapy for unresectable, recurrent, or metastatic disease and in the adjuvant setting after surgery for patients with high risk of recurrence (Joensuu et al., 2001; Demetri et al....
Per package insert from the manufacturer, most common adverse reactions include myelosuppression, diarrhea, headache, skin rash, fatigue, nausea, and musculoskeletal pain, but there were no reports of grade 3 or 4 adverse reaction, including rhab- domyolysis [4]. )e mechanism of muscle injury ...
The dosage of febuxostat during dasatinib therapy was adjusted according to the package insert. Early molecular response (EMR) was defined as BCR::ABL1IS≤ 10 % at three months after dasatinib treatment. Major molecular response (MMR) was defined as BCR::ABL1IS≤ 0.1 % at 12 months ...